News Center

Discover all of the trending news of the Ipsen Group

68 results

September 20, 2019

How data analysis can outpace the lab to answer clinically pressing questions

[caption id="attachment_5663" align="alignnone" width="226"] Ulf Staginnus, SVP, Head Global Market Access & Pricing at Ipsen[/caption] Hepatocellular carcinoma (HCC) is a complex and difficult disease to treat, and a diagnosis…


September 16, 2019

#WeWontRest in using digital innovation to transform patients’ lives

[caption id="" align="aligncenter" width="262"] Harout Semerjian, EVP, Chief Commercial Officer, Ipsen[/caption] The European Federation of Pharmaceutical Industries and Associations (EFPIA) recently launched the next phase of EFPIA’s #WeWontRest campaign…


July 18, 2019

Ipsen will hold a conference call Thursday, 25 July 2018 at 2:30 p.m. (Paris time).

Participants should dial in to the call approximately five to ten minutes prior to its start. No reservation is required to participate in the conference call. Standard International: +44 (0)…


July 15, 2019

COSMIC-021 trial

As part of Ipsen’s ongoing commitment to improve outcomes for patients with high unmet medical needs, we are pleased to announce an update to the COSMIC-021 trial. Our partner, Exelixis,…


June 24, 2019

Fulfilling our Bold Promise Through External Innovation

Ivana Magovčević-Liebisch Ph.D., J.D. Executive Vice-President, Chief Business Officer It has just been a year since I joined Ipsen and I’m thrilled to have experienced the courageous, entrepreneurial…


June 17, 2019

It’s time to talk about kidney cancer!

World Kidney Cancer Day is on 20 June, an event created by the International Kidney Cancer Coalition (IKCC) to raise awareness of this deadly, but forgotten disease. Kidney cancer is…


May 31, 2019

How Ipsen is making patient-centric innovation a reality

Bartek Bednarz, Ipsen, Senior Vice-President, Oncology Franchise The world of healthcare is changing. Patients are no longer bystanders in their treatment journey, but integral members of the care team. They…


May 13, 2019

Ipsen – Investor Day 2019

To register for the webcast, please Click here.


April 29, 2019

Standby statement on lanreotide generic

Paris (France), April 29, 2019 - Following information regarding the filing of a generic long-acting lanreotide (Somatuline®) formulation with the FIMEA, the Finnish Medicines Agency, Ipsen believes that it…


April 18, 2019

Ipsen completes acquisition of Clementia Pharmaceuticals

Today, Ipsen announced the closing of the acquisition of Clementia Pharmaceuticals. A Canadian clinical-stage biotech company, Clementia is focused on innovative new treatments for people with rare bone disorders and…


April 4, 2019

Ipsen is present at ESGE Days with an educational symposium and two oral presentations

ESGE DAYS 2019 is the second edition of a congress dedicated to increasing quality of care, establishing guidelines for best practice and developing educational program in endoscopy. Taking place from…


March 13, 2019

Building the market access ecosystem

At Eyeforpharma 2019, Ipsen’s Senior VP Market Access, Ulf Staginnus is participating in a session about fostering genuine payment innovation with stakeholder collaboration to match rapidly increasing treatment effectiveness.…


March 8, 2019

Ipsen champions women in leadership and gender equality this International Women’s Day!

International Women’s Day is a great opportunity to celebrate our extraordinary female colleagues around the world! Their significant contribution continues to make Ipsen shine on the world stage and we…


February 25, 2019

Ipsen acquisition of Clementia Pharmaceuticals – Conference

Ipsen will host a conference call and web conference today to discuss this announcement. Participants should dial in approximately 5 to 10 minutes prior to the start. No reservation is…


February 6, 2019

Ipsen reiterated its commitment to the Innobio-2 fund

On February 4, 2019, Ipsen was delighted to attend the presentation of the new CSF Industries and Health Technologies sector contract at the Ministry of Economy and Finance. The health…


January 22, 2019

Ipsen commits to making all its published scientific research freely accessible to everyone

We aim to publish the results of our clinical studies in peer-reviewed medical and scientific journals, whatever the outcome. Patients are increasingly engaged with understanding and managing their own healthcare…


January 16, 2019

Ipsen announces 50 posters to be presented at the 2019 TOXINS Congress – January 16-19

TOXINS is a key conference for thought leaders – clinicians and researchers from academia and industry – in the field of neurotoxins and especially Botulinum toxins. Taking place this year…


January 9, 2019

JP Morgan Conference

Click here to access the webcast.


January 8, 2019

Ipsen: a story of transformation and growth

On December 12th, at the closing ceremony of the prestigious French Finance congress, Financium, Aymeric Le Chatelier, EVP, Chief Financial Officer, was awarded a trophy of “CFO of the Year – Special Award…


December 31, 2018

Ipsen Seasons greetings

​A New Year has come​ and it's a wonderful time to reflect on what matters most. For us, patients remain our priority all year long. That's why embodying a patient-centric…


November 28, 2018

Ipsen France signs milestone Cancer and Employment Charter at French Cancer National Institute

On Friday, 23rd November, Ipsen France celebrated a significant milestone by signing the Cancer & Employment Charter at an event held at the French Cancer National Institute. By signing this Charter, companies…


October 31, 2018

Ipsen Group inaugurates new office in Singapore

Ipsen, a leading  biopharmaceutical group  dedicated to improving lives through innovative medicines in specialty care (oncology , neuroscience and rare diseases) and Consumer Healthcare, inaugurates a new office in the Central Business District of Singapore on the 1st of…


October 23, 2018

“How France can leverage its attributes and deliver on its full potential” David Meek’s address 7th Series of G5 Santé

Prior to joining Ipsen in 2016 as Chief Executive Officer, I lived in a number of countries around the world including the United States, Italy, Switzerland and Canada. In each…


October 18, 2018

How Ipsen is waging war on cancer by Bartek BEDNARZ

10/18/2018 [caption id="attachment_5094" align="aligncenter" width="315"]       Bartek BEDNARZ, Ipsen, Senior Vice-President, Oncology Franchise[/caption] In the past 12 months we are proud to have advanced our strong contribution to global efforts…


October 10, 2018

Spread the word: it is Liver Cancer Awareness Month

October is Liver Cancer Awareness Month, a global initiative that aims to raise understanding of this challenging disease and educate us all about the signs and symptoms, as well as…


October 5, 2018

Ipsen joins Biotechnology Innovation Organization (BIO) To Advance Growth and Innovation

Ipsen is delighted to join the Biotechnology Innovation Organization (BIO), the largest association of biotechnology companies, academic institutions and biotech centers around the world, and a leader in biotech…


September 28, 2018

Ipsen appoints Dr. Yan Moore as Senior Vice President, Head of Oncology Therapeutic Area; and Dr. Alexander McEwan, FRCPC, as Vice President, Head of Radiopharmaceuticals

Paris (France), 27 September 2018 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the appointments of Dr. Yan Moore and Dr. Alexander “Sandy” McEwan, bringing two R&D leaders into the company’s oncology…


September 21, 2018

Ipsen relocating German affiliate to Munich

Ipsen Pharma GmbH, the German subsidiary of the global specialty-driven biopharmaceutical group Ipsen, has been operating in Germany since 1978. In 2019, the new head office of the biopharmaceutical subsidiary…


June 3, 2018

Boston and Paris – two rich ecosystems of R&D excellence

Sunday 3rd June Today I’m giving the keynote speech at the second Boston-Paris Biotechnology Summit – this year held in Boston. It’s an exciting time. Investment in biotech continues apace here, and the…


May 22, 2018


On May 23rd, the Stroke Alliance for Europe (SAFE) and the European Stroke Organization (ESO) are presenting the Stroke Action Plan for Europe (2018-2030) at the European Parliament in Brussels. Ipsen is…


March 19, 2018

Ipsen Named One of the Best Workplaces in Ireland

Ipsen was recognised as the 12th Best Medium Workplace in Ireland 2018. The Great Place to Work Institute defines a great place to work as one where employees trust the…


March 19, 2018 awarded as Most valuable patient initiative by Eyeforpharma Awards 2018* is a dedicated website for patients living with neuroendocrine tumors that was designed with patients, for patients. Nearly 900 patient questionnaires across the globe were collected to assess the…


February 15, 2018

International Childhood Cancer Day, Ipsen mobilizes its teams

The premise is that all children, no matter what their background, have dreams and aspirations. But for hundreds of thousands of children each year, cancer takes this opportunity away from…


February 14, 2018

Ipsen’s Full Year 2017 Financial Results



January 15, 2018

Ipsen and Exelixis to host joint investor briefing on Phase 3 CELESTIAL trial results presented at ASCO GI

Ipsen and its partner Exelixis will jointly host a live investor briefing at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) on the results of the Phase…


January 15, 2018

Ipsen at ASCO GI 2018

We are excited to be participating in the 2018 ASCO GI congress in San Francisco from the 18th until the 20th of January. Discover all activities Ipsen is organizing and…


January 4, 2018

Ipsen to present at the J.P. Morgan Healthcare Conference – January 10, 2018, at 10:00 am PST

David Meek, CEO will present at the J.P. Morgan Healthcare Conference  in San Francisco, California on Wednesday, January 10, 2018, at 10:00 AM PST (07:00 PM CET).A live webcast will…


December 20, 2017

Ipsen’s partner Exelixis announces U.S. FDA approval of CABOMETYX® Tablets for previously untreated advanced renal cell carcinoma

RCC is the most common form of kidney cancer in adults.The FDA’s priority review and approval of CABOMETYX was based on results from the randomized phase 2 CABOSUN trial in…


December 19, 2017

Ipsen announces its corporate agenda for 2018

15 February 2018: Full year 2017 sales & results 26 April 2018: First quarter 2018 sales 30 May 2018: General shareholders’ meeting 6 June 2018: Payment of 2017 dividend** 26…


December 19, 2017

Ipsen delivers strong sales growth of 22.6% for the third quarter of 2017

Paris (France), 26 October 2017 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced sales for the third quarter of 2017. Financial highlights Q3 2017 Group…


December 18, 2017

Agreement signed for the creation of an Algerian-French joint venture

This took place during the meeting of the Algerian-French high-level intergovernmental Committee (CIHN), at the Hotel de Matignon in Paris, in the presence of the Algerian and French Prime Ministers,…


December 18, 2017

Dr James A. Levine appointed President of the Fondation IPSEN

"I am delighted to accept the Presidency of the Fondation IPSEN which plays an important role in the development and dissemination of scientific knowledge. Having spent my career in…


December 4, 2017

Ipsen to Present at the Citi 2017 Global Healthcare Conference

David Meek, CEO will present at the Citi 2017 Global Healthcare Conference in New York on Thursday, December 7, 2017, at 11:45 AM EST (05:45 PM CET).A live webcast will…


November 10, 2017

Ipsen supports awareness of Neuroendocrine Tumors (NET) and the NET Cancer Day on November 10, 2017

NET Cancer Day, a global initiative of the International Neuroendocrine Cancer Alliance (INCA) and its members, aims to inform and raise awareness of this often undetected and rare disease…


October 31, 2017

Ipsen launches a website designed with patients for patients is intended for patients who have just been diagnosed or patients who have been living with the condition for some time.It is a new online resource…


October 10, 2017

Dr Sotirios Stergiopoulos appointed as the new President of the Board of Governors of Accreditation Council for Medical Affairs (ACMA).

Dr Sotirios Stergiopoulos, Senior Vice-President & Head of Global Medical Affairs at Ipsen Bioscience, has been appointed as the new President of the Board of Governors of Accreditation Council for…


September 7, 2017

Ipsen at ESMO 2017

Want to know more about the activities Ipsen is organising and data we are sharing at this year’s ESMO ? Visit our new website* to learn more ! We…


July 25, 2017

Ipsen’s First Half 2017 Financial Results

Financial Community: audio broadcast will start at 04:00 CEST Click here to access audio webcast France and continental Europe: +33 (0)1 7099 3534 UK: +44 (0)20 7162 9960 US: +1…


April 26, 2017

Ipsen’s Investor Day

On May 11, 2017, Ipsen hosted an Investor Day during which David Meek (CEO) and Aymeric Le Chatelier (Executive Vice President, Finance), along with other members of the Executive Leadership…


March 6, 2017

Discover Ipsen new clinical trials section

Visit the new clinical trials section


February 9, 2017

Ipsen’s 2016 Full Year Results

David Meek, CEO Aymeric Le Chatelier, Executive Vice President, Finance have been presenting Ipsen's 2016 full year results on Thursday 23rd February 2017. > Click here to access the press…


January 9, 2017

Web conference on Merrimack announcement

Conference call & web conference: Date: 9 January, 2017 Time: 2:30pm CET/ 8:30am EST  Replay available for seven days. Click here or dial: France and continental Europe +33 (0)1 7099 3529…


November 10, 2016

Ipsen launches a new dedicated website for patients living with neuroendocrine tumours: built with patients for patients*

An uncommon and relatively unknown disease Neuroendocrine tumors (NETs) are most commonly found in the gastrointestinal tract. Sometimes asymptomatic, they can secrete abnormally high amounts of hormones that affect body…


October 17, 2016

Latest news on the cabozantinib program

During this conference, Exelixis and Ipsen management and invited guest speakers have reviewed and provided context of the results from the Cabosun study, along with the other data sets on…


August 1, 2016

FDA Approval of Dysport® for injection for the treatment of Lower Limb Spasticity in children aged two and older

A condition in which there is an abnormal increase in muscle tone or stiffness Spasticity is a condition in which there is an abnormal increase in muscle tone or stiffness…


July 22, 2016

Positive CHMP opinion for CabometyxTM (cabozantinib)

Accelerated review procedure The positive CHMP opinion was adopted following an accelerated review procedure reserved for medicinal products expected to be of major public health interest. The recommendation will now…


March 31, 2016

Top Tweets 2015

[View the story "#InCaseYouMissedIt " on Storify]


January 8, 2016

Aepodia integrates Ipsen’s R&D Campus in Paris-Saclay biotechnology hub

[caption id="attachment_2410" align="alignleft" width="300"] R&D center in Les Ulis[/caption]Aepodia is a solution provider company specialized in early clinical development of medicinal products and medical devices up to clinical Proof-of-Concept (Phase…


October 14, 2015

Celebration of Ipsen Canadian Headquarters Grand Opening in Mississauga, Ontario

From left to right: Lyndal Walker, Marc de Garidel, Hon. Dipika Damerla, Cynthia Schwalm, Marc Trouyet.Ipsen will join Ontario’s growing biomedical cluster and deliver innovative specialty medicines based on its expertise and leadership in…


July 22, 2015

Opening of a new manufacturing facility in Russia

The opening ceremony was held with participation of Olga Kazanskaya, Vice-Governor of Saint Petersburg, Marc de Garidel, Chairman of Board and Chief Executive Officer of Ipsen, David Panikashvili, President of…


March 27, 2015

A new R&D center in Cambridge (USA)

Ipsen’s state-of-the-art R&D center is located in Cambridge, one of the world’s most vibrant biomedical science and biotechnology hubs, with the exceptional environment of universities and academic institutions, prestigious hospitals…


© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2019